Special Issue

Pheochromocytoma, Paraganglioma and Neuroblastoma: Focus on Genetics—the Never-Ending Story

Message from the Guest Editor

Pheochromocytoma, paraganglioma (PPGL) and neuroblastoma (NB) are tumours with a common embryonal origin in the neural crest that have a challenging diagnosis due to their heterogeneous location and highly variable clinical presentation. PPGL are rare tumours that show the highest percentage of heritability of all human cancers, with 40% of PPGL harbouring a germline mutation (70–80% in the case of paediatric patients). Another 30% of patients have a somatic mutation. To date, 25 PPGL-associated genes have been described and the list is growing. Although familial neuroblastoma was thought to account for only 1–2% of cases, in 2023, 13.9% of NBs were found to harbour germline pathogenic variants in cancer predisposition genes. Early knowledge of genetic status is key to achieving better patient management, developing tumour-tailored treatments and improving the survival of patients with PPGLNB. In this Special Issue, we focus on new developments in genetic diagnostics and their direct impact on patient management.

Guest Editor

Dr. María Currás-Freixes
Centro Nacional de Investigaciones Oncológicas, C/ Melchor Fernández Almagro, 28029 Madrid, Spain

Deadline for manuscript submissions

30 September 2025

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/227070

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)